This Phase II trial, sponsored by the National Cancer Institute, aimed to evaluate the efficacy of a combination therapy for patients with relapsed multiple myeloma post-autologous stem cell transplant. The study was terminated early due to insufficient patient accrual, with only two patients enrolled. The limited enrollment raises concerns regarding market viability and competitive positioning against existing therapies for multiple myeloma, such as daratumumab and carfilzomib. Companies considering similar combination therapies may need to reassess their clinical development strategies and patient recruitment approaches in this indication.